Worst Biotech CEO of 2011 poll. Gold actually was lauded with the Best Biotech CEO Award last year, so his fall from grace is even more breathtaking. Knowing Gold as I do, he'll work hard in 2012 to snag another Best CEO nomination -- if his angry shareholders don't kick him out first. Runner-up with 30% of the vote was KV Pharma's ( KV-A) Greg Divis Jr. for his magnificent Makena-marketing mishaps. Third place went to Mannkind's ( MNKD) Al Mann, followed by Amarin's ( AMRN) Joseph Zakrzewski and Gilead Sciences' ( GILD) John Martin. Gold takes home the Nance Trophy named in recognition of David Nance, the former CEO of now bankrupt and defunct Introgen Therapeutics. Few CEOs in biotech did more to hone the fine craft of investor bamboozlement and outright incompetence as Introgen's Nance. Gold joins a pantheon of chief executive screw-ups: Elan's ( ELN) Kelly Martin, Genzyme's Henri Termeer and Dan Bradbury of Amylin Pharmaceuticals ( AMLN). Many readers admonished me for failing to nominate Cell Therapeutics ( CTIC) CEO Jim Bianco. As I've said before, he's actually the Worst Biotech CEO Emeritus. Besides, Cell Therapeutics is down only 36% this year, about half that of 2010.
Yes, Bianco will argue that he deserves a raise. His patsy board will undoubtedly oblige. Rajiv Gandhi, the long-dead Indian prime minister contacted me from beyond the grave requesting I name Doug MacLellan of Radient Pharmaceuticals ( RXPC) this year's Worst Biotech CEO. I considered the request but decided MacLellan deserved some mercy. In addition to the embarrassment of boasting about holding business talks with a government official dead for 20 years, MacLellan is still recovering from the pseudo-partnership with the Mayo Clinic, Radient's massive loan default, the reluctant disclosure that its India joint venture was a bust and the delisting from the Amex. Did I mention that Radient's stock price is down 99.5% this year? Other worthy biotech CEO poseurs for 2011: Adventrx Pharmaceuticals' ( ANX) Brian Culley for providing the FDA with a year of laughter.
Cyclacel Pharmaceuticals' ( CYCC) Spiro Rombotis, because my Twitter stream is filled with investors who really dislike you. Exelixis' ( EXEL) Michael Morrisey for whispering into investor ears that the FDA was going to be OK with the cabozantinib SPA -- except it wasn't. Cel-Sci's ( CVM) Geert Kersten: Perennial worst. Randy Mills of Osiris Therpaeutics ( OSIR): Ditto. Somaxon Pharma's ( SOMX) Richard Pascoe for putting everyone to sleep -- except customers (which he doesn't have). Apricus Biosciences' ( APRI) Bassam Damaj, because "penile burning" isn't a "warming sensation." --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.